Metropolis Healthcare Ltd Reports Strong Financial Performance for FY 2018-19
Metropolis Healthcare Ltd (NSE: METROPOLIS | BSE: 542650), a leading diagnostic service provider in India, announced its financial results for the fiscal year 2018-19, reflecting robust growth and operational strength.
Financial Highlights (FY 2018-19 vs FY 2017-18):
Consolidated revenue grew by 18.1%
EBITDA before CSR, one-time share-based, and other expenses stood at INR 2,073 million
Profit After Tax (PAT) before CSR and one-time expenses was INR 1,308 million
Earnings Per Share (EPS): INR 24.06
Key Growth Drivers:
Metropolis witnessed strong performance with a 15.5% increase in patient visits, accompanied by a 5.4% rise in revenue per patient and an 8.5% increase in revenue per test. The company maintained overall margins while outperforming industry growth benchmarks.
Network Expansion and Patient Reach:
The company expanded its laboratory network to 119 labs from 106 in the previous year, primarily through its asset-light ‘Lab on Lease’ model. Its patient service network — comprising owned Patient Service Centers (PSCs), Assisted Referral Centers (ARCs), and third-party PSCs — grew 5.5 times between FY16 and FY19, with 79% of this growth occurring in the last two years alone. This young and expanding network is poised to drive rapid growth in the short and medium term.
Leadership Commentary:
Ms. Ameera Shah, Managing Director of Metropolis Healthcare, said,
"FY19 marks our first financial year as a listed company and has concluded positively with healthy topline growth. We anticipate sustained growth fueled by rapid network expansion, enhanced customer experience, and advancements in technology. Our focus remains on delivering superior quality diagnostics and compassionate care to patients who trust us in their most anxious moments."
Wellness Initiatives:
In February 2019, Metropolis launched 'Truhealth,' a wellness initiative across 36 cities aimed at increasing preventive healthcare awareness and promoting customized wellness packages. This initiative positions Metropolis strongly within the fast-growing wellness diagnostics segment, which accounted for 7-9% of the market in FY18 and is expected to grow at a CAGR of approximately 20% over the next three years (Source: Frost & Sullivan).
Specialized Testing Portfolio:
During the year, the company introduced over 24 super-specialized tests focusing on cancer diagnosis, genetic disorders, neurological conditions, and infectious diseases.
Customer Experience Excellence:
Metropolis consistently maintained a high Net Promoter Score (NPS) of 85 across its group in FY19, reflecting strong brand loyalty and customer satisfaction. This achievement is attributed to the company’s commitment to trust, quality, and service excellence.
Scientific and Medical Excellence:
As of March 2019, Metropolis employed 201 doctors and pathologists, supported by 2,236 scientific officers and phlebotomists. Its academic team published 11 scientific papers in national and international indexed journals during the year.
Technology and Talent Development:
The company upgraded its core IT infrastructure to enhance revenue generation, optimize costs, improve operational efficiency, and elevate customer experience. Additionally, Metropolis conducted its inaugural MEDENGAGE Scholarship Summit in December 2018, nurturing future medical talent and strengthening ties with the medical community.
About Metropolis Healthcare Ltd:
Metropolis Healthcare Ltd is one of India’s leading diagnostic companies by revenue (as of March 31, 2018) with operations across 19 states. Offering over 3,487 clinical laboratory tests and 530 profiles—including advanced diagnostics in cancer, neurological disorders, infectious diseases, and genetic abnormalities—Metropolis is recognized globally for quality, with a CAP proficiency score exceeding 98% over the past decade. The company’s philosophy combines technological superiority, patient-centric service, and reliable diagnostic results to impact millions of lives annually.
.jpg)